Overview Dividends

(ECL) Ecolab - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2788651006

Water Treatment, Hygiene Products, Infection Prevention, Pest Control

EPS (Earnings per Share)

EPS (Earnings per Share) of ECL over the last years for every Quarter: "2020-09": 1.15, "2020-12": 1.23, "2021-03": 0.91, "2021-06": 1.22, "2021-09": 1.41, "2021-12": 1.28, "2022-03": 0.82, "2022-06": 1.1, "2022-09": 1.3, "2022-12": 1.27, "2023-03": 0.88, "2023-06": 1.24, "2023-09": 1.54, "2023-12": 1.55, "2024-03": 1.34, "2024-06": 1.68, "2024-09": 1.83, "2024-12": 1.81, "2025-03": 1.5, "2025-06": 1.89, "2025-09": 2.07,
EPS CAGR: 19.44%
EPS Trend: 81.2%
Last SUE: 0.00σ
Qual. Beats: 0

Revenue

Revenue of ECL over the last years for every Quarter: 2020-09: 3018.6, 2020-12: 3065.3, 2021-03: 2885, 2021-06: 3162.7, 2021-09: 3320.8, 2021-12: 3364.6, 2022-03: 3266.7, 2022-06: 3580.6, 2022-09: 3669.3, 2022-12: 3671.2, 2023-03: 3571.6, 2023-06: 3852.1, 2023-09: 3958.1, 2023-12: 3938.4, 2024-03: 3751.9, 2024-06: 3985.8, 2024-09: 3998.5, 2024-12: 4005.2, 2025-03: 3695, 2025-06: 4025.2, 2025-09: 4165,
Revenue CAGR: 4.70%
Revenue Trend: 64.3%
Last SUE: 2.10σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 19.2%
Value at Risk 5%th 30.3%
Relative Tail Risk -4.04%
Reward TTM
Sharpe Ratio 0.43
Alpha 1.29
Character TTM
Hurst Exponent 0.527
Beta 0.560
Beta Downside 0.517
Drawdowns 3y
Max DD 17.26%
Mean DD 3.47%
Median DD 2.31%

Description: ECL Ecolab September 26, 2025

Ecolab Inc. (NYSE:ECL) delivers water, hygiene, and infection-prevention solutions worldwide through four reportable segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The company’s product portfolio spans water-treatment chemicals, cleaning and sanitizing agents, and pest-control services, sold via field sales teams, corporate accounts, distributors, and dealers.

In FY 2023 Ecolab generated roughly $13.5 billion in revenue, with an adjusted operating margin of about 14 % and a free-cash-flow conversion rate near 70 %. The Global Industrial segment remains the largest revenue driver, benefiting from rising demand for water-recycling technologies in energy-intensive industries, while the Healthcare & Life Sciences segment is gaining traction as hospitals and pharma firms increase spending on infection-control protocols post-COVID-19.

Key macro-economic levers include global industrial production growth (especially in emerging markets), tightening environmental regulations that spur water-conservation investments, and inflationary pressure on raw-material costs, which can compress margins if not offset by pricing power. Ecolab’s historical ability to pass through cost increases and its focus on recurring service contracts provide a partial hedge against these risks.

For a deeper, data-driven look at Ecolab’s valuation scenarios and sensitivity analyses, the resources available on ValueRay may prove helpful.

ECL Stock Overview

Market Cap in USD 74,168m
Sub-Industry Specialty Chemicals
IPO / Inception 1988-01-05
Return 12m vs S&P 500 -2.13%
Analyst Rating 3.73 of 5

ECL Dividends

Metric Value
Dividend Yield 0.97%
Yield on Cost 5y 1.28%
Yield CAGR 5y 5.71%
Payout Consistency 93.2%
Payout Ratio 35.8%

ECL Growth Ratios

Metric Value
CAGR 3y 24.05%
CAGR/Max DD Calmar Ratio 1.39
CAGR/Mean DD Pain Ratio 6.93
Current Volume 1484.6k
Average Volume 1560k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.98b TTM) > 0 and > 6% of Revenue (6% = 953.4m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA -2.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 18.37% (prev 8.99%; Δ 9.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 2.63b > Net Income 1.98b (YES >=105%, WARN >=100%)
Net Debt (6.87b) to EBITDA (3.43b) ratio: 2.00 <= 3.0 (WARN <= 3.5)
Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.21% (target <= -2.0% for YES)
Gross Margin 44.32% (prev 43.15%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 69.09% (prev 70.92%; Δ -1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 9.58 (EBITDA TTM 3.43b / Interest Expense TTM 282.3m) >= 6 (WARN >= 3)

Altman Z'' 4.11

(A) 0.12 = (Total Current Assets 7.11b - Total Current Liabilities 4.19b) / Total Assets 23.90b
(B) 0.52 = Retained Earnings (Balance) 12.48b / Total Assets 23.90b
(C) 0.12 = EBIT TTM 2.70b / Avg Total Assets 23.00b
(D) 0.77 = Book Value of Equity 10.94b / Total Liabilities 14.14b
Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.89

1. Piotroski 6.50pt
2. FCF Yield 1.92%
3. FCF Margin 9.78%
4. Debt/Equity 0.91
5. Debt/Ebitda 2.00
6. ROIC - WACC (= 5.77)%
7. RoE 21.58%
8. Rev. Trend 64.29%
9. EPS Trend 81.16%

What is the price of ECL shares?

As of November 24, 2025, the stock is trading at USD 267.07 with a total of 1,484,550 shares traded.
Over the past week, the price has changed by +4.54%, over one month by -2.89%, over three months by -3.82% and over the past year by +9.25%.

Is ECL a buy, sell or hold?

Ecolab has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold ECL.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 13
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ECL price?

Issuer Target Up/Down from current
Wallstreet Target Price 291.8 9.2%
Analysts Target Price 291.8 9.2%
ValueRay Target Price 292.5 9.5%

ECL Fundamental Data Overview November 21, 2025

Market Cap USD = 74.17b (74.17b USD * 1.0 USD.USD)
P/E Trailing = 37.5718
P/E Forward = 30.1205
P/S = 4.6675
P/B = 7.4509
P/EG = 2.7344
Beta = 0.989
Revenue TTM = 15.89b USD
EBIT TTM = 2.70b USD
EBITDA TTM = 3.43b USD
Long Term Debt = 8.05b USD (from longTermDebt, last quarter)
Short Term Debt = 176.5m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.87b USD (from netDebt column, last quarter)
Enterprise Value = 81.04b USD (74.17b + Debt 8.83b - CCE 1.96b)
Interest Coverage Ratio = 9.58 (Ebit TTM 2.70b / Interest Expense TTM 282.3m)
FCF Yield = 1.92% (FCF TTM 1.55b / Enterprise Value 81.04b)
FCF Margin = 9.78% (FCF TTM 1.55b / Revenue TTM 15.89b)
Net Margin = 12.49% (Net Income TTM 1.98b / Revenue TTM 15.89b)
Gross Margin = 44.32% ((Revenue TTM 15.89b - Cost of Revenue TTM 8.85b) / Revenue TTM)
Gross Margin QoQ = 44.79% (prev 44.78%)
Tobins Q-Ratio = 3.39 (Enterprise Value 81.04b / Total Assets 23.90b)
Interest Expense / Debt = 0.63% (Interest Expense 55.3m / Debt 8.83b)
Taxrate = 17.83% (128.0m / 717.7m)
NOPAT = 2.22b (EBIT 2.70b * (1 - 17.83%))
Current Ratio = 1.70 (Total Current Assets 7.11b / Total Current Liabilities 4.19b)
Debt / Equity = 0.91 (Debt 8.83b / totalStockholderEquity, last quarter 9.72b)
Debt / EBITDA = 2.00 (Net Debt 6.87b / EBITDA 3.43b)
Debt / FCF = 4.43 (Net Debt 6.87b / FCF TTM 1.55b)
Total Stockholder Equity = 9.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.30% (Net Income 1.98b / Total Assets 23.90b)
RoE = 21.58% (Net Income TTM 1.98b / Total Stockholder Equity 9.20b)
RoCE = 15.68% (EBIT 2.70b / Capital Employed (Equity 9.20b + L.T.Debt 8.05b))
RoIC = 13.05% (NOPAT 2.22b / Invested Capital 17.03b)
WACC = 7.28% (E(74.17b)/V(83.00b) * Re(8.08%) + D(8.83b)/V(83.00b) * Rd(0.63%) * (1-Tc(0.18)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 79.79% ; FCFE base≈1.73b ; Y1≈1.95b ; Y5≈2.61b
Fair Price DCF = 158.7 (DCF Value 44.94b / Shares Outstanding 283.2m; 5y FCF grow 14.34% → 3.0% )
EPS Correlation: 81.16 | EPS CAGR: 19.44% | SUE: 0.0 | # QB: 0
Revenue Correlation: 64.29 | Revenue CAGR: 4.70% | SUE: 2.10 | # QB: 1

Additional Sources for ECL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle